Ensysce Biosciences Stock (NASDAQ:ENSC)


RevenueOwnershipFinancialsChart

Previous Close

$0.65

52W Range

$0.14 - $2.06

50D Avg

$0.33

200D Avg

$0.61

Market Cap

$8.63M

Avg Vol (3M)

$25.06M

Beta

0.85

Div Yield

-

ENSC Company Profile


Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

7

IPO Date

Mar 14, 2018

Website

ENSC Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22
M P A R-$2.01M

Fiscal year ends in Dec 23 | Currency in USD

ENSC Financial Summary


Dec 23Dec 22Dec 21
Revenue$2.23M$2.52M$3.53M
Operating Income$-10.72M$-24.22M$-19.87M
Net Income$-10.63M$-24.96M$-29.15M
EBITDA$-10.72M$-24.22M$-19.87M
Basic EPS$-4.69$-138.73$-346.89
Diluted EPS$-4.69$-138.73$-346.89

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
BDRXBiodexa Pharmaceuticals Plc
BWVOnconetix, Inc.
KPRXKiora Pharmaceuticals, Inc.
PXMDPaxMedica, Inc. Common Stock
PHIOPhio Pharmaceuticals Corp.
REVBRevelation Biosciences, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
HILSTharimmune, Inc.
VRAXVirax Biolabs Group Limited
ALLRAllarity Therapeutics, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.
ZURAZura Bio Limited
CDIOCardio Diagnostics Holdings, Inc.
ATNF180 Life Sciences Corp.